Atlanta, GA – According to filings with the U.S. Securities and Exchange Commission, Vero Biotech is raising $99,530,958.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Brent Furse played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Vero Biotech
Vero biotech is an emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled nitric oxide (NO) delivery systems to address unmet medical needs of patients with cardiopulmonary conditions. At Vero Biotech, our mission is to improve the lives of patients by leading the development of innovative technologies for inhaled NO delivery in the acute care hospital setting and beyond, wherever Nitric Oxide treatment is needed. We strive to exceed customer expectations in terms of safety, efficacy, and growth by focusing on the science, development, and commercialization of our innovations.

To learn more about Vero Biotech, visit http://www.vero-biotech.com/

Contact:
Brent Furse, President and Chief Executive Officer
877-337-4118
https://www.linkedin.com/in/brentfurse/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved